Samsung Biologics. (Photo=Samsung Biologics).

 

[Alpha Biz= Reporter Kim Sangjin] Korea Ratings (HanShin) upgraded the credit rating outlook for Samsung Biologics (207940) from "AA- (Stable)" to "AA- (Positive)" on November 29, citing the company’s strong business competitiveness in the antibody drug Contract Development and Manufacturing Organization (CDMO) market.

A "positive" outlook indicates a higher likelihood of a future credit rating upgrade. Samsung Biologics has firmly established its position in the CDMO market based on its excellent technological capabilities. As of the end of September, the company’s order backlog reached $6.7 billion (approximately 9.35 trillion KRW), showing strong performance.

 

 

[ⓒ AlphaBIZ. 무단전재-재배포 금지]